U.S. Markets open in 8 hrs 11 mins

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.80+0.18 (+1.55%)
At close: 4:00PM EDT

Sangamo Therapeutics, Inc.

7000 Marina Boulevard
Brisbane, CA 94005
United States
510 970 6000

Full Time Employees413

Key Executives

NameTitlePayExercisedYear Born
Dr. Alexander D. MacraeCEO, Pres & Director1.2MN/A1963
Mr. Gary H. LoebExec. VP, Gen. Counsel, Chief Compliance Office & Sec.612.2kN/A1970
Dr. R. Andrew Ramelmeier Ph.D.Exec. VP of Technical Operations675.48kN/A1962
Mr. D. Mark McClungExec. VP & Chief Bus. Officer568kN/A1963
Ms. Prathyusha Duraibabu CPA, M.B.A.Sr. VP & CFON/AN/A1979
Dr. Jason D. Fontenot Ph.D.Sr. VP & Chief Scientific OfficerN/AN/A1970
Ms. Aron FeingoldHead of Corp. Communications & Investor Relations OfficerN/AN/AN/A
Ms. Whitney JonesSr. VP & Chief People OfficerN/AN/AN/A
Dr. Nathalie Dubois-StringfellowSr. VP of Product Devel. & ManagementN/AN/AN/A
Ms. Heather EricksonChief of StaffN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Corporate Governance

Sangamo Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 3. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.